Aristolochic Acid in the Etiology of Renal Cell Carcinoma

Background: Aristolochia species used in the practice of traditional herbal medicine contains aristolochic acid (AA), an established human carcinogen contributing to urothelial carcinomas of the upper urinary tract. AA binds covalently to genomic DNA, forming aristolactam (AL)–DNA adducts. Here we investigated whether AA is also an etiologic factor in clear cell renal cell carcinoma (ccRCC). Methods: We conducted a population-based case–control study to investigate the linkage between Aristolochia prescription history, cumulative AA consumption, and ccRCC incidence in Taiwan (5,709 cases and 22,836 matched controls). The presence and level of mutagenic dA-AL-I adducts were determined in the kidney DNA of 51 Taiwanese ccRCC patients. The whole-exome sequences of ccRCC tumors from 10 Taiwanese ccRCC patients with prior exposure to AA were determined. Results: Cumulative ingestion of more than 250 mg of AA increased risk of ccRCC (OR, 1.25), and we detected dA-AL-I adducts in 76% of Taiwanese ccRCC patients. Furthermore, the distinctive AA mutational signature was evident in six of 10 sequenced ccRCC exomes from Taiwanese patients. Conclusions: This study strongly suggests that AA contributes to the etiology of certain RCCs. Impact: The current study offers compelling evidence implicating AA in a significant fraction of the RCC arising in Taiwan and illustrates the power of integrating epidemiologic, molecular, and genetic data in the investigation of cancer etiology. Cancer Epidemiol Biomarkers Prev; 25(12); 1600–8. ©2016 AACR.

[1]  M. Bihoreau,et al.  Aristolochic acid exposure in Romania and implications for renal cell carcinoma , 2015, British Journal of Cancer.

[2]  D. Lambrechts,et al.  Genomic landscape of carcinogen-induced and genetically induced mouse skin squamous cell carcinoma , 2015, Nature Medicine.

[3]  X. Castells,et al.  Renal cell carcinomas of chronic kidney disease patients harbor the mutational signature of carcinogenic aristolochic acid , 2015, International journal of cancer.

[4]  Swe Swe Myint,et al.  Mutation signatures implicate aristolochic acid in bladder cancer development , 2015, Genome Medicine.

[5]  Nansheng Chen,et al.  Mutational landscape of intrahepatic cholangiocarcinoma , 2014, Nature Communications.

[6]  Hiromi Nakamura,et al.  Trans-ancestry mutational landscape of hepatocellular carcinoma genomes , 2014, Nature Genetics.

[7]  Edgars Celms,et al.  Variation in genomic landscape of clear cell renal cell carcinoma across Europe , 2014, Nature Communications.

[8]  S. Rorive,et al.  Exceptionally long‐term persistence of DNA adducts formed by carcinogenic aristolochic acid I in renal tissue from patients with aristolochic acid nephropathy , 2014, International journal of cancer.

[9]  David T. W. Jones,et al.  Signatures of mutational processes in human cancer , 2013, Nature.

[10]  P. A. Futreal,et al.  Genome-Wide Mutational Signatures of Aristolochic Acid and Its Application as a Screening Tool , 2013, Science Translational Medicine.

[11]  K. Kinzler,et al.  Mutational Signature of Aristolochic Acid Exposure as Revealed by Whole-Exome Sequencing , 2013, Science Translational Medicine.

[12]  Steven J. M. Jones,et al.  Comprehensive molecular characterization of clear cell renal cell carcinoma , 2013, Nature.

[13]  Boping Zhou,et al.  Exome sequencing of hepatitis B virus–associated hepatocellular carcinoma , 2012, Nature Genetics.

[14]  C. Iden,et al.  Biomonitoring of aristolactam-DNA adducts in human tissues using ultra-performance liquid chromatography/ion-trap mass spectrometry. , 2012, Chemical research in toxicology.

[15]  Arthur P. Grollman,et al.  Aristolochic acid-associated urothelial cancer in Taiwan , 2012, Proceedings of the National Academy of Sciences.

[16]  B. Jelaković,et al.  Aristolactam-DNA adducts are a biomarker of environmental exposure to aristolochic acid. , 2012, Kidney international.

[17]  A. Grollman,et al.  Lack of recognition by global-genome nucleotide excision repair accounts for the high mutagenicity and persistence of aristolactam-DNA adducts , 2011, Nucleic acids research.

[18]  Huanming Yang,et al.  Frequent mutations of genes encoding ubiquitin-mediated proteolysis pathway components in clear cell renal cell carcinoma , 2011, Nature Genetics.

[19]  Shao-Qing Cai,et al.  Aristolochic acid nephropathy: variation in presentation and prognosis. , 2012, Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association.

[20]  A. Kibel Population-Based Case–Control Study of Chinese Herbal Products Containing Aristolochic Acid and Urinary Tract Cancer Risk , 2010 .

[21]  F. Bob,et al.  Therapeutic Remedies Based on Aristolochia clematitis in the Main Foci of Balkan Endemic Nephropathy in Romania , 2010, Nephron Clinical Practice.

[22]  Pau-Chung Chen,et al.  Population-Based Case–Control Study of Chinese Herbal Products Containing Aristolochic Acid and Urinary Tract Cancer Risk , 2010, Journal of the National Cancer Institute.

[23]  J. Scarborough,et al.  Chapter 7 Aristolochic Acid Nephropathy: An Environmental and Iatrogenic Disease , 2009 .

[24]  Jung-Der Wang,et al.  Prescription profile of potentially aristolochic acid containing Chinese herbal products: an analysis of National Health Insurance data in Taiwan between 1997 and 2003 , 2008, Chinese medicine.

[25]  F. Debellé,et al.  Aristolochic acid nephropathy: a worldwide problem. , 2008, Kidney international.

[26]  B. Jelaković,et al.  Aristolochic acid and the etiology of endemic (Balkan) nephropathy , 2007, Proceedings of the National Academy of Sciences.

[27]  A. Grollman,et al.  Selective Toxicity of Aristolochic Acids I and II , 2007, Drug Metabolism and Disposition.

[28]  H. Schut,et al.  Novel LC-ESI/MS/MS(n) method for the characterization and quantification of 2'-deoxyguanosine adducts of the dietary carcinogen 2-amino-1-methyl-6-phenylimidazo[4,5-b]pyridine by 2-D linear quadrupole ion trap mass spectrometry. , 2007, Chemical research in toxicology.

[29]  Poonam,et al.  Naturally occurring aristolactams, aristolochic acids and dioxoaporphines and their biological activities. , 2003, Natural product reports.

[30]  M. Wiessler,et al.  Formation and persistence of specific purine DNA adducts by 32P-postlabelling in target and non-target organs of rats treated with aristolochic acid I. , 1993, IARC scientific publications.

[31]  J. Simon,et al.  A role for sunlight in skin cancer: UV-induced p53 mutations in squamous cell carcinoma. , 1991, Proceedings of the National Academy of Sciences of the United States of America.

[32]  B. Vogelstein,et al.  p53 mutations in human cancers. , 1991, Science.

[33]  M. Wiessler,et al.  DNA adduct formation of aristolochic acid I and II in vitro and in vivo. , 1988, Carcinogenesis.

[34]  P. Carroll,et al.  Abnormalities at chromosome region 3p12-14 characterize clear cell renal carcinoma. , 1987, Cancer genetics and cytogenetics.